Navigation Links
Henry Ford Hospital study: hVISA linked to high mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA.

The study is being presented Sunday at the 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston.

"Based on our findings, we recommend that hospitals consider routine testing for hVISA," says Katherine Reyes, M.D., a Henry Ford Hospital Internal Medicine physician and the study's lead author. "It remains controversial how differently we will manage these patients upfront. Close follow-up on these patients to make sure their infection is resolved or controlled may save lives."

MRSA, or Methicillin-resistant Staphylococcus aureus, is a bacterium that is resistant to common antibiotics like penicillin. It can cause skin, bloodstream and surgical wound infections and pneumonia. The majority of infections occur among patients in hospitals or other health care settings, though a growing number of infections are being acquired by otherwise healthy people outside those settings.

MRSA strains can be resistant to many drugs, though they are typically susceptible to the antibiotic vancomycin. MRSA infections are often treated with vancomycin administered intravenously.

The study followed 521 patients with MRSA bloodstream infections who were admitted between January 2006 to September 2009 to Henry Ford, an 805-bed tertiary care hospital, education and research complex in Detroit. These infections were screened for heteroresistance, and 19 hVISA cases were identified.

Dr. Reyes and researchers then compared characteristics and outcomes of the 19 hVISA patients against 19 non-hVISA patients, eliminating such factors as age, source of infection and level of sickness. The results:

  • Six hVISA patients died within 30 days compared to three non-hVISA patients.
  • Twelve hVISA patients died within 90 days compared to six non-hVISA patients.
  • Five hVISA patients saw their infection return after 90 days compared to zero for non-hVISA patients.
  • hVISA patients stayed on average four more days in the hospital than non-hVISA patients.
  • hVISA patients were more likely to have received vancomycin in the past.


Contact: David Olejarz
Henry Ford Health System

Related medicine news :

1. The Henry Ford Production System LEAN training for health care
2. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
3. Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament
4. Sung-Cheng (Henry) Huang receives 2010 Benedict Cassen Prize for Research in Nuclear Medicine
5. Henry Gabelnick receives lifetime achievement award
6. Henry Ford Hospital study: Fewer infections with new heart-pump implant
7. Henry Ford Hospital: New left-side heart pump improves right-side heart function
8. Henry Ford Hospital study: Less prep needed for colonoscopy
9. Henry Ford Health System goes radical: Creating the hospital of the future
10. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
11. Henry Ford Hospital study: Shoulder function not fully restored after surgery
Post Your Comments:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: